| 摘要: |
| 目的 系统比较非维生素K抗凝拮抗药(NOACs)与华法林在治疗颅内静脉窦血栓的疗效和安全性。方法 通过计算机检索国内外发表的NOACs与华法林治疗颅内静脉窦血栓的RCTs和前瞻性的队列研究,提取数据后用Review Manager 5.4 软件进行数据处理。结果 根据Meta分析结果显示,使用NOACs治疗颅内静脉窦血栓患者的静脉血栓复发率、静脉血栓部分再通率、静脉血栓完全再通率、死亡发生率、大出血发生率、颅内出血发生率均与使用华法林进行抗凝治疗的患者无显著统计学差异,但良好临床结局优于华法林组。结论 NOACs与华法林在治疗颅内静脉窦血栓(CVST)患者的有效性与安全性相当。 |
| 关键词: 颅内静脉窦血栓 直接口服抗凝药 利伐沙班 阿哌沙班 艾多沙班 达比加群 华法林 Meta分析 |
| DOI:10.13506/j.cnki.jpr.2026.05.015 |
| 基金项目: |
|
Received Date:May 13, 2025
Revision Date:July 09, 2025
Publication Date:May 29, 2026
|
|
| Meta-analysis of the efficacy and safety of NOACs versus Warfarin in the treatment of cerebral venous sinus thrombosis |
| CHANG Yuanyuan1,OU Yiyang2,YE Huirong1,WEN Enhui1 |
| (1. The First Affiliated Hospital of Xi'an Medical University, Xi'an 710082, China;2.Xi'an Medical University, Xi'an 710000, China) |
| Abstract: |
| Objective To systematically compare the efficacy and safety of non vitamin K antagonist (NOACs) and warfarin in the treatment of cerebral venous sinus thrombosis.Methods Randomized controlled trials (RCTs) and prospective cohort studies on the treatment of cerebral venous sinus thrombosis with NOACs and warfarin published at home and abroad were retrieved by computer. After the data were extracted, Review Manager 5.4 software was used for data processing.Results According to the results of Meta-analysis, there were no significant statistical differences in the recurrence rate of venous thrombosis, partial recanalization rate of venous thrombosis, complete recanalization rate of venous thrombosis, mortality rate, incidence of major bleeding and incidence of intracranial hemorrhage between patients with cerebral venous sinus thrombosis treated with NOACs and those treated with warfarin for anticoagulation, but the good clinical outcomes of the NOACs group were better than those of the warfarin group.Conclusion The efficacy and safety of NOACs are comparable to those of warfarin in the treatment of patients with cerebral venous sinus thrombosis (CVST). |
| Key words: Cerebral venous sinus thrombosis Direct oral anticoagulants Rivaroxaban Apixaban Edoxaban Dabigatran Warfarin Meta-analysis |